308 related articles for article (PubMed ID: 35495127)
61. Epigenetic priming by Dot1l in lymphatic endothelial progenitors ensures normal lymphatic development and function.
Yoo H; Lee YJ; Park C; Son D; Choi DY; Park JH; Choi HJ; La HW; Choi YJ; Moon EH; Saur D; Chung HM; Song H; Do JT; Jang H; Lee DR; Park C; Lee OH; Cho SG; Hong SH; Kong G; Kim JH; Choi Y; Hong K
Cell Death Dis; 2020 Jan; 11(1):14. PubMed ID: 31908356
[TBL] [Abstract][Full Text] [Related]
62. Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases.
Wakeman TP; Wang Q; Feng J; Wang XF
EMBO J; 2012 May; 31(9):2169-81. PubMed ID: 22373577
[TBL] [Abstract][Full Text] [Related]
63. Structural basis of recognition and destabilization of the histone H2B ubiquitinated nucleosome by the DOT1L histone H3 Lys79 methyltransferase.
Jang S; Kang C; Yang HS; Jung T; Hebert H; Chung KY; Kim SJ; Hohng S; Song JJ
Genes Dev; 2019 Jun; 33(11-12):620-625. PubMed ID: 30923167
[TBL] [Abstract][Full Text] [Related]
64. Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
Nassa G; Salvati A; Tarallo R; Gigantino V; Alexandrova E; Memoli D; Sellitto A; Rizzo F; Malanga D; Mirante T; Morelli E; Nees M; Åkerfelt M; Kangaspeska S; Nyman TA; Milanesi L; Giurato G; Weisz A
Sci Adv; 2019 Feb; 5(2):eaav5590. PubMed ID: 30775443
[TBL] [Abstract][Full Text] [Related]
65. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
66. Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
Ju Han H; Sub Byun W; Ho Lee G; Kyung Kim W; Jang K; Yang S; Yang J; Woo Ha M; Hong S; Lee J; Shin J; Bong Oh K; Kook Lee S; Park HG
Bioorg Med Chem; 2021 Apr; 35():116072. PubMed ID: 33636429
[TBL] [Abstract][Full Text] [Related]
67. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
[TBL] [Abstract][Full Text] [Related]
68. Targeting the Histone Methyltransferase Disruptor of Telomeric Silencing 1-Like Restricts Avian Leukosis Virus Subgroup J Replication by Restoring the Innate Immune Response in Chicken Macrophages.
Chen S; Wang D; Liu Y; Zhao R; Wu T; Hu X; Pan Z; Cui H
Front Microbiol; 2020; 11():603131. PubMed ID: 33363525
[TBL] [Abstract][Full Text] [Related]
69. Targeting of histone methyltransferase DOT1L plays a dual role in chemosensitization of retinoblastoma cells and enhances the efficacy of chemotherapy.
Mao Y; Sun Y; Wu Z; Zheng J; Zhang J; Zeng J; Lee C; Kim JK
Cell Death Dis; 2021 Dec; 12(12):1141. PubMed ID: 34887387
[TBL] [Abstract][Full Text] [Related]
70. DOT1L promotes cell proliferation and invasion by epigenetically regulating STAT5B in renal cell carcinoma.
Hou Y; Huang S; Liu J; Wang L; Yuan Y; Liu H; Weng X; Chen Z; Hu J; Liu X
Am J Cancer Res; 2023; 13(1):276-292. PubMed ID: 36777512
[TBL] [Abstract][Full Text] [Related]
71. Deletion of the prorenin receptor in the ureteric bud in mice inhibits Dot1/H3K79 pathway.
Song R; Yosypiv IV
Pediatr Res; 2024 Jan; ():. PubMed ID: 38287105
[TBL] [Abstract][Full Text] [Related]
72. Histone methyltransferase Dot1L is a coactivator for thyroid hormone receptor during
Wen L; Fu L; Shi YB
FASEB J; 2017 Nov; 31(11):4821-4831. PubMed ID: 28739643
[TBL] [Abstract][Full Text] [Related]
73. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Nguyen AT; Taranova O; He J; Zhang Y
Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
[TBL] [Abstract][Full Text] [Related]
74. Maternal DOT1L is dispensable for mouse development.
Liao J; Szabó PE
Sci Rep; 2020 Nov; 10(1):20636. PubMed ID: 33244015
[TBL] [Abstract][Full Text] [Related]
75. Computational modeling reveals key molecular properties and dynamic behavior of disruptor of telomeric silencing 1-like (DOT1L) and partnering complexes involved in leukemogenesis.
Stodola TJ; Chi YI; De Assuncao TM; Leverence EN; Tripathi S; Dsouza NR; Mathison AJ; Volkman BF; Smith BC; Lomberk G; Zimmermann MT; Urrutia R
Proteins; 2022 Jan; 90(1):282-298. PubMed ID: 34414607
[TBL] [Abstract][Full Text] [Related]
76. AF10 (MLLT10) prevents somatic cell reprogramming through regulation of DOT1L-mediated H3K79 methylation.
Uğurlu-Çimen D; Odluyurt D; Sevinç K; Özkan-Küçük NE; Özçimen B; Demirtaş D; Enüstün E; Aztekin C; Philpott M; Oppermann U; Özlü N; Önder TT
Epigenetics Chromatin; 2021 Jul; 14(1):32. PubMed ID: 34215314
[TBL] [Abstract][Full Text] [Related]
77. Targeting histone methylation for colorectal cancer.
Huang T; Lin C; Zhong LL; Zhao L; Zhang G; Lu A; Wu J; Bian Z
Therap Adv Gastroenterol; 2017 Jan; 10(1):114-131. PubMed ID: 28286564
[TBL] [Abstract][Full Text] [Related]
78. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Vatapalli R; Sagar V; Rodriguez Y; Zhao JC; Unno K; Pamarthy S; Lysy B; Anker J; Han H; Yoo YA; Truica M; Chalmers ZR; Giles F; Yu J; Chakravarti D; Carneiro B; Abdulkadir SA
Nat Commun; 2020 Aug; 11(1):4153. PubMed ID: 32814769
[TBL] [Abstract][Full Text] [Related]
79. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
80. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
